Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Inhibition of type 1 IGF receptor (IGF-1R) sensitizes to DNA-damaging cancer treatments, and delays repair of DNA double strand breaks (DSBs) by non-homologous end-joining and homologous recombination (HR). In a recent screen for mediators of resistance to IGF-1R inhibitor AZ12253801, we identified RAD51, required for the strand invasion step of HR. These findings prompted us to test the hypothesis that IGF-1R-inhibited cells accumulate DSBs formed at endogenous DNA lesions, and depend on residual HR for their repair. Indeed, initial experiments showed time-dependent accumulation of γH2AX foci in IGF-1R -inhibited or -depleted prostate cancer cells. We then tested effects of suppressing HR, and found that RAD51 depletion enhanced AZ12253801 sensitivity in PTEN wild-type prostate cancer cells but not in cells lacking functional PTEN. Similar sensitization was induced in prostate cancer cells by depletion of BRCA2, required for RAD51 loading onto DNA, and in BRCA2(-/-) colorectal cancer cells, compared with isogenic BRCA2(+/-) cells. We also assessed chemical HR inhibitors, finding that RAD51 inhibitor BO2 blocked RAD51 focus formation and sensitized to AZ12253801. Finally, we tested CDK1 inhibitor RO-3306, which impairs HR by inhibiting CDK1-mediated BRCA1 phosphorylation. R0-3306 suppressed RAD51 focus formation consistent with HR attenuation, and sensitized prostate cancer cells to IGF-1R inhibition, with 2.4-fold reduction in AZ12253801 GI50 and 13-fold reduction in GI80. These data suggest that responses to IGF-1R inhibition are enhanced by genetic and chemical approaches to suppress HR, defining a population of cancers (PTEN wild-type, BRCA mutant) that may be intrinsically sensitive to IGF-1R inhibitory drugs.

Original publication

DOI

10.1002/ijc.29327

Type

Journal article

Journal

Int J Cancer

Publication Date

15/06/2015

Volume

136

Pages

2961 - 2966

Keywords

BRCA2, DNA repair, IGF-1R inhibitor, RAD51, biomarker, homologous recombination, type 1 IGF receptor, BRCA1 Protein, BRCA2 Protein, Blotting, Western, Boron Compounds, CDC2 Protein Kinase, Cell Line, Tumor, Cell Survival, Colorectal Neoplasms, DNA Breaks, Double-Stranded, DNA Repair, Histones, Homologous Recombination, Humans, Isoxazoles, Male, Microscopy, Fluorescence, PTEN Phosphohydrolase, Phosphorylation, Prostatic Neoplasms, Pyrimidines, Quinolines, RNA Interference, Rad51 Recombinase, Receptor, IGF Type 1, Thiazoles